Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin vs Rifabutin for MAC Prevention in HIV
NCT00001030Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of clarithromycin and rifabutin in Mycobacterium avium complex infection (MAC) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence of MAC bacteremia or disseminated MAC disease at 24 months. Status: completed.
02
Drugs
clarithromycinrifabutin
03
Conditions
Mycobacterium avium complex infection (MAC)
Beyond the preview
Go deeper on NCT00001030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001030.